Meridian Bioscience
78 articles about Meridian Bioscience
-
Meridian Bioscience Reports Third Quarter Fiscal 2021 Results
8/6/2021
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2021.
-
Meridian Closes Acquisition of BreathTek® Business
8/2/2021
Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced that it closed the previously announced acquisition of the North American BreathTek® business from Otsuka America Pharmaceutical, Inc. effective July 31, 2021.
-
Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H. pylori from Otsuka America Pharmaceutical, Inc.
7/23/2021
Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it signed a definitive agreement to acquire the North American BreathTek® business from Otsuka America Pharmaceutical, Inc. for $20 million in cash.
-
Meridian Bioscience to Hold Third Quarter Fiscal 2021 Financial Results Conference Call on August 6, 2021
7/14/2021
Meridian Bioscience, Inc. will report third quarter fiscal 2021 financial results Friday, August 6, 2021.
-
Meridian Bioscience Announces Preliminary Revenue Results for Fiscal 2021 Third Quarter
7/13/2021
Meridian Bioscience, Inc. today provided preliminary revenue results for its third quarter of fiscal 2021.
-
Meridian Resubmits Application to FDA for Emergency Use Authorization for Revogene® SARS-CoV-2 Molecular Assay
6/28/2021
Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has re-submitted its application for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for the company’s SARS-CoV-2 molecular diagnostic test on the Revogene® platform.
-
Meridian’s New Master Mix for LAMP Assays Offers a Practical Solution for POC Molecular Detection of RNA viruses
6/16/2021
Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of the Lyo-Ready™ RT-LAMP Mix, specifically designed for accelerating the development of ambient temperature stable reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) assays.
-
Meridian Bioscience to Participate in the 41st Annual William Blair Growth Stock Conference and Jefferies Virtual Healthcare Conference
5/27/2021
Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today participation in two upcoming investor conferences. Jack Kenny, Chief Executive Officer, will participate in a live, virtual fireside chat at the 41st Annual William Blair Growth Stock Conference on Wednesday, June 2, 2021 at 4:20 PM ET.
-
Meridian Bioscience Reports Strong Growth in Net Revenues and EPS in Second Quarter Fiscal 2021
5/7/2021
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2021. Second Quarter 2021 Highlights (Comparison to Second Quarter Fiscal 2020): Consolidated net revenues of $85.3 million, up 49% year-over-year Life Science segment delivered net revenues of $53.3 million, up 139% year-over-year
-
Pfizer reported its first-quarter 2021 revenues of $14.6 billion, an impressive 42% operational growth.
-
Meridian Simplifies Workflows for POC Molecular Tests with a New Lyo-Ready™ LAMP Mix
4/28/2021
Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of the Lyo-Ready™ DNA LAMP Mix, specifically designed for accelerating the development of ambient temperature-stable loop-mediated isothermal amplification (LAMP) assays.
-
Meridian Bioscience to Hold Second Quarter Fiscal 2021 Financial Results Conference Call on May 7, 2021
4/19/2021
Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report second quarter fiscal 2021 financial results Friday, May 7, 2021.
-
Meridian Bioscience Announces FDA Submission for New Curian® Campy Assay
4/1/2021
Meridian Bioscience, Inc. (NASDAQ: VIVO) a leading global provider of diagnostic testing solutions and life science raw materials, today announced that it has made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for the Company’s new Curian ® Campy assay. This assay is one of many assays in the pipeline that expands the Curian ® menu, continuing Meridian’s leadership in the gastrointestinal disease and lateral flow testing mar
-
Meridian Launches its New Air-Dryable Mix for Crude Blood Samples
3/8/2021
Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable Direct DNA qPCR Blood Mix, which is specifically designed for the manufacturing of room-temperature stable molecular diagnostic assays direct from whole blood, serum or plasma.
-
Meridian Bioscience Corrects Prior Update Regarding Revogene® SARS-CoV-2 EUA Withdrawal
2/23/2021
Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, updated its communication regarding the withdrawal of its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene ® platform.
-
Meridian Bioscience Provides an Update on the Revogene® SARS-CoV-2 EUA Submission
2/16/2021
Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, provided an update on its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene ® platform.
-
Meridian Bioscience Reports Record Setting First Quarter Fiscal 2021 Operating Results and Raises Full Year Fiscal 2021 Guidance
2/5/2021
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2020.
-
Meridian Bioscience Expands Production Capacity with Support from NIH, JobsOhio, and the Village of Newtown
2/3/2021
Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it will increase production capacity of the company's SARS-CoV-2 molecular diagnostic test on its Revogene® platform after receiving a $5.5M award from the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative and an additional grant from JobsOhio.
-
Meridian Bioscience to Hold First Quarter Fiscal 2021 Financial Results Conference Call on February 5, 2021
1/13/2021
Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report first quarter fiscal 2021 financial results Friday, February 5, 2021.
-
Meridian Bioscience Announces Better-than-expected Preliminary First Quarter Fiscal 2021 Revenue Results
1/7/2021
Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced preliminary financial results for the first quarter of fiscal 2021.